Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 581 results for pregnancy

  1. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

  2. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  3. In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring intermittent capillary blood glucose monitoring?

    be offered to all women with type 1 diabetes to help women meet their pregnancy blood glucose targets and improve neonatal outcomes. The...

  4. In women with type 1 diabetes who are already pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring?

    be offered to all women with type 1 diabetes to help women meet their pregnancy blood glucose targets and improve neonatal outcomes. The...

  5. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

  6. Alcohol-use disorders: diagnosis and management of physical complications (CG100)

    This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.

  7. Embryo selection for single embryo transfer:- Further research is needed to improve embryo selection to facilitate single embryo transfers.

    maximise the chance of pregnancy. As detailed in the guideline, this practice has inherent risks, especially of multiple...

  8. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

  9. Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)

    NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital

  10. End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

    This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

  11. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  12. When should testing for gestational diabetes take place – in the first or second trimester?

    those from populations with a high incidence of type 2 diabetes) enter pregnancy with undiagnosed type 2 diabetes, but may not be tested...

  13. Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.

  14. Jaundice in newborn babies under 28 days (QS57)

    This quality standard covers recognising and managing jaundice in newborn babies (neonatal jaundice), from birth to 28 days, in primary care (including community care) and secondary care. It describes high-quality care in priority areas for improvement.